Ensysce Biosciences, Inc. (ENSC) stock
ENSCNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.41−0.01 (-2.13%)
Close on Nov 16, 2026Market cap $7.97MP/E –Yield –
Ensysce Biosciences r&d expenses
Research and development expenses are spending on new products and technology.
Ensysce Biosciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $12.39M, up 33.2% year over year. For fiscal 2025 it was $10.38M, up 43.7% from the year before. The highest annual figure on record is $19.84M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.38M | +43.7% |
| FY2024 | Dec 31, 2024 | $7.22M | -4.9% |
| FY2023 | Dec 31, 2023 | $7.59M | -61.7% |
| FY2022 | Dec 31, 2022 | $19.84M | +322.9% |
| FY2021 | Dec 31, 2021 | $4.69M | +6.8% |
| FY2020 | Dec 31, 2020 | $4.39M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.47M | +28.5% |
| Q1 FY2026 | Mar 31, 2026 | $3.35M | +77.5% |
| Q4 FY2025 | Dec 31, 2025 | $3.61M | -5.0% |
| Q3 FY2025 | Sep 30, 2025 | $2.95M | +74.8% |
| Q2 FY2025 | Jun 30, 2025 | $1.92M | +103.1% |
| Q1 FY2025 | Mar 31, 2025 | $1.89M | +142.1% |
| Q4 FY2024 | Dec 31, 2024 | $3.80M | +70.3% |
| Q3 FY2024 | Sep 30, 2024 | $1.69M | -11.7% |
| Q2 FY2024 | Jun 30, 2024 | $947.23K | -42.4% |
| Q1 FY2024 | Mar 31, 2024 | $778.90K | -56.6% |
| Q4 FY2023 | Dec 31, 2023 | $2.23M | -65.3% |
| Q3 FY2023 | Sep 30, 2023 | $1.91M | -59.7% |
| Q2 FY2023 | Jun 30, 2023 | $1.64M | -69.1% |
| Q1 FY2023 | Mar 31, 2023 | $1.80M | -42.8% |
| Q4 FY2022 | Dec 31, 2022 | $6.44M | +194.4% |
| Q3 FY2022 | Sep 30, 2022 | $4.76M | +177.4% |
| Q2 FY2022 | Jun 30, 2022 | $5.31M | +1046.6% |
| Q1 FY2022 | Mar 31, 2022 | $3.14M | +1004.2% |
| Q4 FY2021 | Dec 31, 2021 | $2.19M | +74.6% |
| Q3 FY2021 | Sep 30, 2021 | $1.71M | +92.0% |
| Q2 FY2021 | Jun 30, 2021 | $463.22K | -67.0% |
| Q1 FY2021 | Mar 31, 2021 | $284.38K | – |
| Q4 FY2020 | Dec 31, 2020 | $1.25M | – |
| Q3 FY2020 | Sep 30, 2020 | $892.99K | – |
| Q2 FY2020 | Jun 30, 2020 | $1.40M | – |
See a number that looks wrong?